Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Main Category > Main Forum

Reply
 
Thread Tools Display Modes
  #1  
Old 07-19-2012, 11:36 AM
Dross Dross is offline
Moderator
 
Join Date: Nov 2006
Posts: 883
Default Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatmen

PHILADELPHIA — Inhibitors of indoleamine 2,3-dioxygenase (IDO) are being assessed in clinical trials as a potential treatment for recurrent or refractory solid tumors. Clear genetic rationale for these trials, together with evidence that primary and metastatic lung tumors might be particularly susceptible to the drugs, is now reported in a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

"Our data provide preclinical genetic validation for the ongoing clinical trials testing IDO inhibitors in cancer patients," said Alexander Muller, Ph.D., associate professor at Lankenau Institute for Medical Research in Wynnewood, Pa. "We also believe that our results indicate that these drugs could have particular impact in patients with lung adenocarcinoma and lung metastases, conditions for which there is an urgent, unmet need for new therapeutic options.

"The ongoing clinical trials were initiated based on pharmacological studies that indicated that IDO inhibitors can enhance the effectiveness of other therapies in mouse models of cancer. Genetic evidence to support the concept was lacking. Muller and his colleagues, therefore, set out to determine the effect of disrupting the IDO gene on tumor development in mice.

"It was very important to us to use models of disease as physiologically relevant as possible," he said. "We chose the KRAS-induced lung carcinoma model as our model of primary disease since tumors can be induced selectively in the lung and are driven by mutations in a gene known to be affected in approximately 20 percent of nonsmall cell lung cancers. We modeled metastatic disease using the 4T1 mouse breast cancer cell line, which very efficiently metastasizes to the lung after being engrafted in the mammary glands of mice. This is one of only a few breast cancer models with the capacity to metastasize efficiently to sites affected in human breast cancer patients.

"Genetically-induced IDO deficiency reduced lung tumor burden and improved survival in both models."This genetic confirmation of the importance of IDO in lung tumor development is essential support for the clinical trials," said Muller. "However, we were also hoping to garner insight into the mechanisms by which IDO impacts tumor development. In this regard, our findings linking IDO to increased vascularization and modification of the inflammatory environment are critical. These data indicate that IDO has a far more expansive role in tumorigenesis than we might have thought.

"Analysis of differences between the lungs of IDO-sufficient and -deficient tumor-bearing mice in the KRAS-induced lung carcinoma model revealed that levels of the pro-inflammatory molecule IL-6 were markedly lower in the absence of IDO. Levels of this known tumor-promoting factor were also lower in the model of metastasis when IDO was absent.

Additional work in the model of metastasis indicated that IDO-potentiated IL-6 production and promoted metastasis to the lung by driving the expansion and immunosuppressive function of a population of cells known as myeloid-derived suppressor cells (MDSCs). MDSCs are well-characterized, potent inhibitors of antitumor immune responses.

"It was very satisfying to be able to experimentally close the loop and clearly define a mechanism by which IDO promotes metastatic outgrowth to the lung, at least in the 4T1 breast cancer model," said Muller. "We think that this mechanism might also link with the vascular effects of IDO. IDO promotes tumorigenesis in many different ways, and we are looking to see if we can take clinical advantage of some of these.

"Muller has financial interests in the clinical development of IDO inhibitors for the purpose of treating cancer and other diseases.

Last edited by gdpawel : 08-13-2012 at 12:34 AM. Reason: post full article
Reply With Quote
  #2  
Old 08-13-2012, 12:29 AM
gdpawel gdpawel is offline
Moderator
 
Join Date: Feb 2007
Location: Pennsylvania
Posts: 4,354
Default Targeting Cancer With New Strategies

This is another strategy of targeting cancer via the immune system. Cancer cells are our own cells gone awry and our immune system doesn't always see cancer as an invader. A tumor is smart, changing just enough to stay out of the line of fire. Tumors and T cells (the cellular arm of the immune system and main player in anti-tumor immunity) cohabitate for many years before a tumor grows. Researchers at various institutions are packaging an antigen gene that will alert the immune system in a novel delivery system while quashing the body's misguided efforts to protect a tumor.

It is antigens (proteins on or in all cells) that get the attention of the immune system. Dendritic cells present antigens to T cells so that the host immune system will be alerted. Researchers are taking key antigens and modifying them just enough to get the attention of T cells but still result in an immune response that targets the cancer. One difference from conventional vaccines is that tumor vaccines need to work where tumor growth is established. Tumors impede the work by not just flying under the radar screen but actually suppressing the immune response.

One of those suppressive mechanisms is the enzyme IDO (indoleamine 2,3-dioxygenase). Tumors use IDO for protection by activating regulatory T cells, which has a suppressive effect on the anti-tumor immune response. They hope to enable a comprehensive treatment package that includes a T cell vaccine and an IDO inhibitor to optimize the therapeutic effect in cancer patients. Looks like they are moving from animal models into human beings (clinical trial). Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer.

[url]http://cancerfocus.org/forum/showthread.php?t=847
__________________
Gregory D. Pawelski
Reply With Quote
Sponsored Links
Advertisement
Reply


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -5. The time now is 05:18 AM.